| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 194.6 | 118.7 |
| Net income | -668.3 | -12.6 |
| EPS (diluted, $ a share) | $-14.40 | $-0.30 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +63.9% |
|---|---|
| Operating margin | -340.3% |
10-Q filed with the SEC, NASDAQ: TARS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Tarsus Pharmaceuticals, Inc.: key numbers
- Share price
- $78.68Close, Nov 16
- Market cap
- $3.88B
- Shares outstanding
- 49.31MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Tarsus Pharmaceuticals, Inc.
All →Tarsus Pharmaceuticals Financial Results
Tarsus Pharmaceuticals reported record third quarter 2026 financial results, highlighted by XDEMVY net product sales of $194.6 million, a 64% year-over-year increase. The company surpassed one million bottles dispensed and $1 billion in cumulative net sales since the product's launch, while also announcing the appointment of Neera Clase as Chief Commercial Officer.
“XDEMVY has shown what that focus can achieve. In just three years since launch, we have dispensed more than one million bottles and generated $1 billion in cumulative net product sales, and with continued robust growth, we are only getting started. That strength is helping us build one of the most differentiated pipelines in eye care, with the potential to bring five medicines to patients in the next five years.”
Bobby Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus
Tarsus Pharmaceuticals M&A Deal with Alkeus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals filed an amendment to its previous 8-K to provide required historical and pro forma financial statements following its acquisition of Alkeus Pharmaceuticals. The acquisition was originally completed on September 4, 2026, pursuant to a merger agreement dated July 31, 2026.
- Counterparty
- Alkeus Pharmaceuticals, Inc.